Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis

Open access
Fauster, A, Rebsamen, M, Huber, K V M, Bigenzahn, J W, Stukalov, A, Lardeau, C-H, Scorzoni, S, Bruckner, M, Gridling, M, Parapatics, K, Colinge, J, Bennett, K L, Kubicek, S, Krautwald, S, Linkermann, A, Superti-Furga, G·2015·Cell Death & Disease

Abstract

Necroptosis is a form of regulated necrotic cell death mediated by receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3. Necroptotic cell death contributes to the pathophysiology of several disorders involving tissue damage, including myocardial infarction, stroke and ischemia-reperfusion injury. However, no inhibitors of necroptosis are currently in clinical use. Here we performed a phenotypic screen for small-molecule inhibitors of tumor necrosis factor-alpha (TNF-α)-induced necroptosis in Fas-associated protein with death domain (FADD)-deficient Jurkat cells using a representative panel of Food and Drug Administration (FDA)-approved drugs. We identified two anti-cancer agents, ponatinib and pazopanib, as submicromolar inhibitors of necroptosis. Both compounds inhibited necroptotic cell death induced by various cell death receptor ligands in human cells, while not protecting from apoptosis. Ponatinib and pazopanib abrogated phosphorylation of mixed lineage kinase domain-like protein (MLKL) upon TNF-α-induced necroptosis, indicating that both agents target a component upstream of MLKL. An unbiased chemical proteomic approach determined the cellular target spectrum of ponatinib, revealing key members of the necroptosis signaling pathway. We validated RIPK1, RIPK3 and transforming growth factor-β-activated kinase 1 (TAK1) as novel, direct targets of ponatinib by using competitive binding, cellular thermal shift and recombinant kinase assays. Ponatinib inhibited both RIPK1 and RIPK3, while pazopanib preferentially targeted RIPK1. The identification of the FDA-approved drugs ponatinib and pazopanib as cellular inhibitors of necroptosis highlights them as potentially interesting for the treatment of pathologies caused or aggravated by necroptotic cell death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cddis.2015.130

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 188

Metadata

Authors
Fauster, A., Rebsamen, M., Huber, K. V. M., Bigenzahn, J. W., Stukalov, A., Lardeau, C.-H., Scorzoni, S., Bruckner, M., Gridling, M., Parapatics, K., Colinge, J., Bennett, K. L., Kubicek, S., Krautwald, S., Linkermann, A., & Superti-Furga, G.
Venue
Cell Death & Disease
Published
2015-05-21
Volume
6
Issue
5
Pages
e1767-e1767
ISSN
2041-4889 (ISSN-L)
OpenAlex
W231086871
Cited by
188
References
22
FWCI
7.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. https://app.cochat.ai/papers/10.1038/cddis.2015.130
The paper
Fauster, A., Rebsamen, M., Huber, K. V. M., Bigenzahn, J. W., Stukalov, A., Lardeau, C.-H., Scorzoni, S., Bruckner, M., Gridling, M., Parapatics, K., Colinge, J., Bennett, K. L., Kubicek, S., Krautwald, S., Linkermann, A., & Superti-Furga, G. (2015). A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death & Disease. https://doi.org/10.1038/cddis.2015.130

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.